<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33329541</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Very Early Involvement of Innate Immunity in Peripheral Nerve Degeneration in SOD1-G93A Mice.</ArticleTitle><Pagination><StartPage>575792</StartPage><MedlinePgn>575792</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">575792</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.575792</ELocationID><Abstract><AbstractText>Recent preclinical and clinical evidence suggest that immune system has a role in the progression and prognosis of Amyotrophic Lateral Sclerosis (ALS), but the identification of a clear mechanism and immune players remains to be elucidated. Here, we have investigated, in 30 and 60 days (presymptomatic) and 120 days (symptomatic) old SOD1-G93A mice, systemic, peripheral, and central innate and adaptive immune and inflammatory response, correlating it with the progression of the neurodegeneration in neuromuscular junction, sciatic nerves, and spinal cord. Surprisingly, we found a very initial (45-60 days) presence of IgG in sciatic nerves together with a gradual enhancement of A20/TNFAIP3 (protein controlling NF-&#x3ba;B signalling) and a concomitantly significant increase and activation of circulating mast cells (MCs) as well as MCs and macrophages in sciatic nerve and an enhancement of IL-6 and IL-10. This immunological frame coincided with a myelin aggregation. The 30-60 days old SOD1-G93A mice didn't show real elements of neuroinflammation and neurodegeneration in spinal cord. In 120 days old mice macrophages and monocytes are widely diffused in sciatic nerves, peripheral neurodegeneration reaches the tip, high circulating levels of TNF&#x3b1; and IL-2 were found and spinal cord exhibits clear signs of neural damage and infiltrating immune cells. Our results underpin a clear immunological disorder at the origin of ALS axonopathy, in which MCs are involved in the initiation and sustaining of inflammatory events. These data cannot be considered a mere epiphenomenon of motor neuron degeneration and reveal new potential selective immune targets in ALS therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Angelini, De Angelis, Vacca, Piras, Parisi, Nutini, Spalloni, Pagano, Longone, Battistini, Pavone and Marinelli.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angelini</LastName><ForeName>Daniela Francesca</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Angelis</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vacca</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>CNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piras</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nutini</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spalloni</LastName><ForeName>Alida</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagano</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longone</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battistini</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavone</LastName><ForeName>Flaminia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinelli</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556062">IL10 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Immunol. 2021 Apr 06;12:682508</RefSource><PMID Version="1">33889160</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015213" MajorTopicYN="Y">Neuroimmunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014855" MajorTopicYN="Y">Wallerian Degeneration</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Wallerian-like degeneration</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">demyelination</Keyword><Keyword MajorTopicYN="N">mast cells</Keyword><Keyword MajorTopicYN="N">monocytes/macrophages</Keyword><Keyword MajorTopicYN="N">peripheral nerve degeneration</Keyword><Keyword MajorTopicYN="N">pro-inflammatory cytokine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33329541</ArticleId><ArticleId IdType="pmc">PMC7714949</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.575792</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The &#x2018;dying-back&#x2019; phenomenon of motor neurons in ALS. J Mol Neurosci (2011) 43:470&#x2013;7. &#xa0;10.1007/s12031-010-9467-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg R, Pascual J. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. 5th ed. Rosenberg R, Pascual J, editors. Academic Press Inc; (2015) 1&#x2013;1464. 10.1016/C2012-0-02688-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/C2012-0-02688-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner N, Cote R, Suster S, Weiss L. Modern Surgical Pathology. 2nd ed. Elsevier Saunders; (2009). p. 1&#x2013;2432.</Citation></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. . Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp Neurol (2004) 185:232&#x2013;40. &#xa0;10.1016/j.expneurol.2003.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Glass JD. Axonal degeneration in motor neuron disease. Neurodegener Dis (2007) 4:431&#x2013;42. &#xa0;10.1159/000107704</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000107704</ArticleId><ArticleId IdType="pubmed">17934327</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonka S, Wiese S, Sendtner M. Axonal Defects in Mouse Models of Motoneuron Disease. J Neurobiol (2004) 58:272&#x2013;86. &#xa0;10.1002/neu.10313</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/neu.10313</ArticleId><ArticleId IdType="pubmed">14704958</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Kaiser A, Price AC. Motor neuron degeneration after sciatic nerve avulsion in adult rat evolves with oxidative stress and is apoptosis. J Neurobiol (1999) 40:185&#x2013;201. 10.1002/(SICI)1097-4695(199908)40:2&lt;185::AID-NEU5&gt;3.0.CO;2-#</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4695(199908)40:2&lt;185::AID-NEU5&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">10413449</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Chaabane L, Peviani M, Ungaro D, Domi T, Dina G, et al. . Defining peripheral nervous system dysfunction in the SOD-1G93A transgenic rat model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2014) 73:658&#x2013;70. &#xa0;10.1097/NEN.0000000000000081</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000081</ArticleId><ArticleId IdType="pubmed">24918640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol (2008) 21:570&#x2013;9. &#xa0;10.1097/ACO.0b013e32830edbdf</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0b013e32830edbdf</ArticleId><ArticleId IdType="pmc">PMC2735048</ArticleId><ArticleId IdType="pubmed">18784481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao H, Zhang YQ. Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev (2008) 32:972&#x2013;83. &#xa0;10.1016/j.neubiorev.2008.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2008.03.009</ArticleId><ArticleId IdType="pubmed">18471878</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, et al. . An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener (2018) 19:242&#x2013;9. &#xa0;10.1080/21678421.2017.1421666</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId><ArticleId IdType="pubmed">29308669</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G, Spampinato AG, Cavallaro S. Neuroinflammation and ALS: Transcriptomic Insights into Molecular Disease Mechanisms and Therapeutic Targets. Mediators Inflammation (2017) 2017:7070469. &#xa0;10.1155/2017/7070469</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7070469</ArticleId><ArticleId IdType="pmc">PMC5610842</ArticleId><ArticleId IdType="pubmed">29081603</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid SI, Ampie L, Kelly R, Ladha SS, Dardis C. Immune modulation in the treatment of amyotrophic lateral sclerosis: A review of clinical trials. Front Neurol (2017) 8:486. &#xa0;10.3389/fneur.2017.00486</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00486</ArticleId><ArticleId IdType="pmc">PMC5622209</ArticleId><ArticleId IdType="pubmed">28993751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP, Bornschlegl S, Butler GW, Maas ML, Kazamel M, et al. . Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PloS One (2017) 12:e0182002. &#xa0;10.1371/journal.pone.0182002</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer AK, Jones KJ, Sanders VM, Walker CL. Temporospatial Analysis and New Players in the Immunology of Amyotrophic Lateral Sclerosis. Int J Mol Sci (2018) 19(631):1&#x2013;16. &#xa0;10.3390/ijms19020631</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19020631</ArticleId><ArticleId IdType="pmc">PMC5855853</ArticleId><ArticleId IdType="pubmed">29473876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasco S, Zaragoza P, Garc&#xed;a-Redondo A, Calvo AC, Osta R. Inflammatory and non-inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis. PloS One (2017) 12:e0184626. &#xa0;10.1371/journal.pone.0184626</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0184626</ArticleId><ArticleId IdType="pmc">PMC5591000</ArticleId><ArticleId IdType="pubmed">28886177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Gen&#xe7; B, Stanford MJ, Pytel P, Roos RP, Weintraub S, et al. . Evidence for an early innate immune response in the motor cortex of ALS. J Neuroinflamm (2017) 14:129. &#xa0;10.1186/s12974-017-0896-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0896-4</ArticleId><ArticleId IdType="pmc">PMC5485686</ArticleId><ArticleId IdType="pubmed">28651542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, de Vito G, Cecchi R, Riva N, Dina G, et al. . Immune response in peripheral axons delays disease progression in SOD1G93A mice. J Neuroinflamm (2016) 13:261. &#xa0;10.1186/s12974-016-0732-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0732-2</ArticleId><ArticleId IdType="pmc">PMC5055725</ArticleId><ArticleId IdType="pubmed">27717377</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Lee JD, Woodruff TM, Henderson RD. The Peripheral Immune System and Amyotrophic Lateral Sclerosis. Front Neurol (2020) 11:279. &#xa0;10.3389/fneur.2020.00279</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00279</ArticleId><ArticleId IdType="pmc">PMC7186478</ArticleId><ArticleId IdType="pubmed">32373052</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Mar Amador M, Vandenberghe N, Berhoune N, Camdessanch&#xe9; J-P, Gronier S, Delmont E, et al. . Unusual association of amyotrophic lateral sclerosis and myasthenia gravis: A dysregulation of the adaptive immune system? Neuromuscul Disord (2016) 26:342&#x2013;6. &#xa0;10.1016/j.nmd.2016.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2016.03.004</ArticleId><ArticleId IdType="pubmed">27102004</ArticleId></ArticleIdList></Reference><Reference><Citation>de Pasqua S, Cavallieri F, D&#x2019;Angelo R, Salvi F, Fini N, D&#x2019;Alessandro R, et al. . Amyotrophic lateral sclerosis and myasthenia gravis: association or chance occurrence? Neurol Sci (2017) 38:441&#x2013;4. &#xa0;10.1007/s10072-016-2787-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-016-2787-3</ArticleId><ArticleId IdType="pubmed">27913903</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology (2013) 81:1222&#x2013;5. &#xa0;10.1212/WNL.0b013e3182a6cc13</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, et al. . The IASP classification of chronic pain for ICD-11: Chronic neuropathic pain. Pain (2019) 160:53&#x2013;9. &#xa0;10.1097/j.pain.0000000000001365</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000001365</ArticleId><ArticleId IdType="pmc">PMC6310153</ArticleId><ArticleId IdType="pubmed">30586071</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci (1994) 124 Suppl:14&#x2013;9. &#xa0;10.1016/0022-510x(94)90171-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(94)90171-6</ArticleId><ArticleId IdType="pubmed">7807136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, Wurster U, Sinzenich T, K&#xf6;rner S, Dengler R, Mohammadi B, et al. . Anti-ganglioside antibodies in amyotrophic lateral sclerosis revisited. PloS One (2015) 10:e0125339. &#xa0;10.1371/journal.pone.0125339</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0125339</ArticleId><ArticleId IdType="pmc">PMC4397083</ArticleId><ArticleId IdType="pubmed">25875836</ArticleId></ArticleIdList></Reference><Reference><Citation>May C, Nordhoff E, Casjens S, Turewicz M, Eisenacher M, Gold R, et al. . Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PloS One (2014) 9:e89596. &#xa0;10.1371/journal.pone.0089596</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089596</ArticleId><ArticleId IdType="pmc">PMC3935926</ArticleId><ArticleId IdType="pubmed">24586901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol Res Int (2011) 2011:497080. &#xa0;10.1155/2011/497080</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/497080</ArticleId><ArticleId IdType="pmc">PMC3150148</ArticleId><ArticleId IdType="pubmed">21826267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez LE, Kotler ML, Vattino LG, Conti E, Reisin RC, Mulatz KJ, et al. . Amyotrophic lateral sclerosis-immunoglobulins selectively interact with neuromuscular junctions expressing P/Q-type calcium channels. J Neurochem (2011) 119:826&#x2013;38. &#xa0;10.1111/j.1471-4159.2011.07462.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07462.x</ArticleId><ArticleId IdType="pubmed">21883225</ArticleId></ArticleIdList></Reference><Reference><Citation>Andjus PR, Khiroug L, Nistri A, Cherubini E. ALS IgGs suppress [Ca2+]i rise through P/Q-type calcium channels in central neurones in culture. Neuroreport (1996) 7:1914&#x2013;6. &#xa0;10.1097/00001756-199608120-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199608120-00008</ArticleId><ArticleId IdType="pubmed">8905691</ArticleId></ArticleIdList></Reference><Reference><Citation>Flink MT, Atchison WD. Ca2+ Channels as Targets of Neurological Disease: Lambert-Eaton Syndrome and Other Ca2+ Channelopathies. J Bioenerg Biomembr (2003) 35:697&#x2013;718. &#xa0;10.1023/B:JOBB.0000008033.02320.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:JOBB.0000008033.02320.10</ArticleId><ArticleId IdType="pubmed">15000529</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamori M, Maruta T, Komai K. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy. Neurosci Res (2000) 36:183&#x2013;91. &#xa0;10.1016/s0168-0102(99)00135-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0168-0102(99)00135-2</ArticleId><ArticleId IdType="pubmed">10683522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitanosono H, Shiraishi H, Motomura M. P/Q-type calcium channel antibodies in lambert-eaton myasthenie syndrome. Brain Nerve (2018) 70:341&#x2013;55. &#xa0;10.11477/mf.1416201007</Citation><ArticleIdList><ArticleId IdType="doi">10.11477/mf.1416201007</ArticleId><ArticleId IdType="pubmed">29632282</ArticleId></ArticleIdList></Reference><Reference><Citation>Alix JJP, Dolphin AC, Fern R. Vesicular apparatus, including functional calcium channels, are present in developing rodent optic nerve axons and are required for normal node of Ranvier formation. J Physiol (2008) 586:4069&#x2013;89. &#xa0;10.1113/jphysiol.2008.155077</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2008.155077</ArticleId><ArticleId IdType="pmc">PMC2652192</ArticleId><ArticleId IdType="pubmed">18599536</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinelli S, Eleuteri C, Vacca V, Strimpakos G, Mattei E, Severini C, et al. . Effects of age-related loss of P/Q-type calcium channels in a mice model of peripheral nerve injury. Neurobiol Aging (2015) 36:352&#x2013;64. &#xa0;10.1016/j.neurobiolaging.2014.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.025</ArticleId><ArticleId IdType="pubmed">25150573</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Blokhuis BR, Garssen J, Redegeld FA. Non-IgE mediated mast cell activation. Eur J Pharmacol (2016) 778:33&#x2013;43. &#xa0;10.1016/j.ejphar.2015.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2015.07.017</ArticleId><ArticleId IdType="pubmed">26164792</ArticleId></ArticleIdList></Reference><Reference><Citation>Malbec O, Da&#xeb;ron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev (2007) 217:206&#x2013;21. &#xa0;10.1111/j.1600-065X.2007.00510.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2007.00510.x</ArticleId><ArticleId IdType="pubmed">17498061</ArticleId></ArticleIdList></Reference><Reference><Citation>Merluzzi S, Frossi B, Gri G, Parusso S, Tripodo C, Pucillo C. Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA-secreting plasma cells. Blood (2010) 115:2810&#x2013;7. &#xa0;10.1182/blood-2009-10-250126</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-10-250126</ArticleId><ArticleId IdType="pubmed">20101023</ArticleId></ArticleIdList></Reference><Reference><Citation>Zouali M, La Cava A. Innate Immunity Pathways in Autoimmune Diseases - PubMed - NCBI. Front Immunol (2019) 10:1245&#x2013;8. 10.3389/978-2-88963-236-7</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/978-2-88963-236-7</ArticleId><ArticleId IdType="pmc">PMC6557999</ArticleId><ArticleId IdType="pubmed">31214194</ArticleId></ArticleIdList></Reference><Reference><Citation>Gri G, Frossi B, D&#x2019;Inca F, Danelli L, Betto E, Mion F, et al. . Mast cell: an emerging partner in immune interaction. Front Immunol (2012) 3:120. &#xa0;10.3389/fimmu.2012.00120</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00120</ArticleId><ArticleId IdType="pmc">PMC3360165</ArticleId><ArticleId IdType="pubmed">22654879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (80- ) (1994) 264:1772&#x2013;5. &#xa0;10.1126/science.8209258</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalloni A, Origlia N, Sgobio C, Trabalza A, Nutini M, Berretta N, et al. Postsynaptic alteration of NR2A subunit and defective autophosphorylation of alphaCaMKII at threonine-286 contribute to abnormal plasticity and mor... - PubMed - NCBI. Cereb Cortex (2011) 21:796&#x2013;805. 10.1093/cercor/bhq152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhq152</ArticleId><ArticleId IdType="pubmed">20732897</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalloni A, Greco V, Ciriminna G, Carregari VC, Marini F, Pieroni L, et al. . Impact of pharmacological inhibition of hydrogen sulphide production in the SOD1G93A-ALS mouse model. Int J Mol Sci (2019) 20(10):2550&#x2013;65. &#xa0;10.3390/ijms20102550</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20102550</ArticleId><ArticleId IdType="pmc">PMC6567312</ArticleId><ArticleId IdType="pubmed">31137614</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacca V, Marinelli S, Pieroni L, Urbani A, Luvisetto S, Pavone F. Higher pain perception and lack of recovery from neuropathic pain in females: A behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. Pain (2014) 155:388&#x2013;402. &#xa0;10.1016/j.pain.2013.10.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2013.10.027</ArticleId><ArticleId IdType="pubmed">24231652</ArticleId></ArticleIdList></Reference><Reference><Citation>Inman CF, Rees LEN, Barker E, Haverson K, Stokes CR, Bailey M. Validation of computer-assisted, pixel-based analysis of multiple-colour immunofluorescence histology. J Immunol Methods (2005) 302:156&#x2013;67. &#xa0;10.1016/j.jim.2005.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2005.05.005</ArticleId><ArticleId IdType="pubmed">15992812</ArticleId></ArticleIdList></Reference><Reference><Citation>Day NC, Wood SJ, Ince PG, Volsen SG, Smith W, Slater CR, et al. . Differential localization of voltage-dependent calcium channel &#x3b1;1 subunits at the human and rat neuromuscular junction. J Neurosci (1997) 17:6226&#x2013;35. &#xa0;10.1523/jneurosci.17-16-06226.1997</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.17-16-06226.1997</ArticleId><ArticleId IdType="pmc">PMC6568369</ArticleId><ArticleId IdType="pubmed">9236233</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin KP, Jiang Z, Brownstone RM. Characterization of calcium currents in functionally mature mouse spinal motoneurons. Eur J Neurosci (2000) 12:1624&#x2013;34. &#xa0;10.1046/j.1460-9568.2000.00050.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2000.00050.x</ArticleId><ArticleId IdType="pubmed">10792440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateno M, Kato S, Sakurai T, Nukina N, Takahashi R, Araki T. Mutant SOD1 impairs axonal transport of choline acetyltransferase and acetylcholine release by sequestering KAP3. Hum Mol Genet (2009) 18:942&#x2013;55. &#xa0;10.1093/hmg/ddn422</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn422</ArticleId><ArticleId IdType="pmc">PMC2640210</ArticleId><ArticleId IdType="pubmed">19088126</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgo L, de Belleroche J, Rossi M, Steiner TJ. Characterisation of the distribution of choline acetyltransferase messenger RNA in human spinal cord and its depletion in motor neurone disease. J Neurol Sci (1992) 112:126&#x2013;32. &#xa0;10.1016/0022-510X(92)90141-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(92)90141-7</ArticleId><ArticleId IdType="pubmed">1469422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T. Choline Acetyltransferase Activities in Single Spinal Motor Neurons from Patients with Amyotrophic Lateral Sclerosis. J Neurochem (1989) 52:636&#x2013;40. &#xa0;10.1111/j.1471-4159.1989.tb09167.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1989.tb09167.x</ArticleId><ArticleId IdType="pubmed">2911033</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Bosco DA, Brown H, Gatto R, Kaminska A, Song Y, et al. . Inhibition of Fast Axonal Transport by Pathogenic SOD1 Involves Activation of p38 MAP Kinase. PloS One (2013) 8(6):e6523. &#xa0;10.1371/journal.pone.0065235</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065235</ArticleId><ArticleId IdType="pmc">PMC3680447</ArticleId><ArticleId IdType="pubmed">23776455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, Bao Cutrona M, Cheroni C, Grignaschi G, Lo Coco D, Peviani M, et al. . Inter- and intracellular signaling in amyotrophic lateral sclerosis: Role of p38 mitogen-activated protein kinase. Neurodegener Dis (2006) 2:128&#x2013;34. &#xa0;10.1159/000089617</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000089617</ArticleId><ArticleId IdType="pubmed">16909017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshenker S. Wallerian degeneration: The innate-immune response to traumatic nerve injury. J Neuroinflamm (2011) 8:109, 1&#x2013;14. &#xa0;10.1186/1742-2094-8-109</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-109</ArticleId><ArticleId IdType="pmc">PMC3179447</ArticleId><ArticleId IdType="pubmed">21878125</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian F, Yang W, Mordes DA, Wang JY, Salameh JS, Mok J, et al. . Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging. Nat Commun (2016) 7:13283&#x2013;98. &#xa0;10.1038/ncomms13283</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13283</ArticleId><ArticleId IdType="pmc">PMC5095598</ArticleId><ArticleId IdType="pubmed">27796305</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti L, Gilley J, Coleman MP. Wallerian degeneration: An emerging axon death pathway linking injury and disease. Nat Rev Neurosci (2014) 15:394&#x2013;409. &#xa0;10.1038/nrn3680</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3680</ArticleId><ArticleId IdType="pubmed">24840802</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng B, Lv W, Duan W, Liu Y, Li Z, Ma Y, et al. . Progressive Degeneration and Inhibition of Peripheral Nerve Regeneration in the SOD1-G93A Mouse Model of Amyotrophic Lateral Sclerosis. Cell Physiol Biochem (2018) 46:2358&#x2013;72. &#xa0;10.1159/000489627</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000489627</ArticleId><ArticleId IdType="pubmed">29742495</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinelli S, Vacca V, Ricordy R, Uggenti C, Tata AM, Luvisetto S, et al. . The Analgesic Effect on Neuropathic Pain of Retrogradely Transported botulinum Neurotoxin A Involves Schwann Cells and Astrocytes. PloS One (2012) 7(10):e47977. &#xa0;10.1371/journal.pone.0047977</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0047977</ArticleId><ArticleId IdType="pmc">PMC3480491</ArticleId><ArticleId IdType="pubmed">23110146</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Obayashi M, Ishiguro T, Sato N, Niimi Y, Ozaki K, et al. . Cytoplasmic location of &#x3b1;1A voltage-gated calcium channel C-terminal fragment (Cav2.1-CTF) aggregate is sufficient to cause cell death. PloS One (2013) 8:e50121. &#xa0;10.1371/journal.pone.0050121</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0050121</ArticleId><ArticleId IdType="pmc">PMC3591409</ArticleId><ArticleId IdType="pubmed">23505410</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Ibarburu S, Barreto-N&#xfa;&#xf1;ez R, Varela V, Moura IC, Dubreuil P, et al. . Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight (2017) 2(20):e95934. &#xa0;10.1172/jci.insight.95934</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.95934</ArticleId><ArticleId IdType="pmc">PMC5846907</ArticleId><ArticleId IdType="pubmed">29046475</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Chen G. Mast cell and autoimmune diseases. Mediators Inflammation (2015) 2015:246126. &#xa0;10.1155/2015/246126</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/246126</ArticleId><ArticleId IdType="pmc">PMC4402170</ArticleId><ArticleId IdType="pubmed">25944979</ArticleId></ArticleIdList></Reference><Reference><Citation>Das T, Chen Z, Hendriks RW, Kool M. A20/Tumor Necrosis Factor &#x3b1;-Induced Protein 3 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models. Front Immunol (2018) 9:104. &#xa0;10.3389/fimmu.2018.00104</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00104</ArticleId><ArticleId IdType="pmc">PMC5826380</ArticleId><ArticleId IdType="pubmed">29515565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi N, Oyama M, Kozuka-Hata H, Inoue J. Involvement of A20 in the molecular switch that activates the non-canonical NF-&#x43a;B pathway. Sci Rep (2013) 3:2568. &#xa0;10.1038/srep02568</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep02568</ArticleId><ArticleId IdType="pmc">PMC3764444</ArticleId><ArticleId IdType="pubmed">24008839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SC. The non-canonical NF-&#x3ba;B pathway in immunity and inflammation. Nat Rev Immunol (2017) 17:545&#x2013;58. &#xa0;10.1038/nri.2017.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.52</ArticleId><ArticleId IdType="pmc">PMC5753586</ArticleId><ArticleId IdType="pubmed">28580957</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;rgens SW, Eckardt K, Jensen J, Drevon CA, Eckel J. Exercise and Regulation of Adipokine and Myokine Production. Prog Mol Biol Trans Sci (Elsevier B.V.) (2015) 135:313&#x2013;36. &#xa0;10.1016/bs.pmbts.2015.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2015.07.002</ArticleId><ArticleId IdType="pubmed">26477920</ArticleId></ArticleIdList></Reference><Reference><Citation>Betto E, Usuelli V, Mandelli A, Badami E, Sorini C, Capolla S, et al. . Mast cells contribute to autoimmune diabetes by releasing interleukin-6 and failing to acquire a tolerogenic IL-10+ phenotype. Clin Immunol (2017) 178:29&#x2013;38. &#xa0;10.1016/j.clim.2015.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2015.12.013</ArticleId><ArticleId IdType="pubmed">26732858</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol (2007) 8:1095&#x2013;104. &#xa0;10.1038/ni1503</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1503</ArticleId><ArticleId IdType="pubmed">17767162</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Velden D, Lagraauw HM, Wezel A, Launay P, Kuiper J, Huizinga TWJ, et al. . Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile. Arthritis Res Ther (2016) 18:138. &#xa0;10.1186/s13075-016-1036-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1036-8</ArticleId><ArticleId IdType="pmc">PMC4907027</ArticleId><ArticleId IdType="pubmed">27296719</ArticleId></ArticleIdList></Reference><Reference><Citation>Madaro L, Passafaro M, Sala D, Etxaniz U, Lugarini F, Proietti D, et al. . Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis. Nat Cell Biol (2018) 20:917&#x2013;27. &#xa0;10.1038/s41556-018-0151-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0151-y</ArticleId><ArticleId IdType="pmc">PMC6145844</ArticleId><ArticleId IdType="pubmed">30050118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, et al. . IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflamm (2010) 7:76. &#xa0;10.1186/1742-2094-7-76</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-76</ArticleId><ArticleId IdType="pmc">PMC2992053</ArticleId><ArticleId IdType="pubmed">21062492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, et al. . Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis (2012) 1:305&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560466</ArticleId><ArticleId IdType="pubmed">23383400</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Fabbrizio P, Amadio S, Napoli G, Verdile V, Morello G, et al. . Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis. Front Immunol (2017) 8:1689. &#xa0;10.3389/fimmu.2017.01689</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01689</ArticleId><ArticleId IdType="pmc">PMC5714870</ArticleId><ArticleId IdType="pubmed">29250069</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Fabbrizio P, Parisi C, Amadio S, Volont&#xe9; C. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol Neurobiol (2016) 53:518&#x2013;31. &#xa0;10.1007/s12035-014-9019-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-9019-8</ArticleId><ArticleId IdType="pubmed">25482048</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Fabbrizio P, Amadio S, Volont&#xe9; C. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J Neuroinflamm (2016) 13:191. &#xa0;10.1186/s12974-016-0658-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0658-8</ArticleId><ArticleId IdType="pmc">PMC4994328</ArticleId><ArticleId IdType="pubmed">27549088</ArticleId></ArticleIdList></Reference><Reference><Citation>Feoktistova M, Makarov R, Brenji S, Schneider AT, Hooiveld GJ, Luedde T, et al. . A20 Promotes Ripoptosome Formation and TNF-Induced Apoptosis via cIAPs Regulation and NIK Stabilization in Keratinocytes. Cells (2020) 9:351. &#xa0;10.3390/cells9020351</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020351</ArticleId><ArticleId IdType="pmc">PMC7072579</ArticleId><ArticleId IdType="pubmed">32028675</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman L. Multiple sclerosis: Two-stage disease. Nat Immunol (2001) 2:762&#x2013;4. &#xa0;10.1038/ni0901-762</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni0901-762</ArticleId><ArticleId IdType="pubmed">11526378</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, et al. . Mast cells and inflammation. Biochim Biophys Acta - Mol Basis Dis (2012) 1822:21&#x2013;33. &#xa0;10.1016/j.bbadis.2010.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2010.12.014</ArticleId><ArticleId IdType="pmc">PMC3318920</ArticleId><ArticleId IdType="pubmed">21185371</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietsch GN, Hinrichs DJ. Mast cell proteases liberate stable encephalitogenic fragments from intact myelin. Cell Immunol (1991) 135:541&#x2013;8. &#xa0;10.1016/0008-8749(91)90297-O</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0008-8749(91)90297-O</ArticleId><ArticleId IdType="pubmed">1709829</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner T, Soffer D, Shalit M, Levi-Schaffer F. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci (1994) 122:210&#x2013;3. &#xa0;10.1016/0022-510X(94)90300-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90300-X</ArticleId><ArticleId IdType="pubmed">7517440</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front Neurosci (2014) 8:252. &#xa0;10.3389/fnins.2014.00252</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Reaume AG, Flood DG, Scott RW, Kowall NW, Ferrante RJ, et al. . Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology (1999) 53:1239&#x2013;46. &#xa0;10.1212/wnl.53.6.1239</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.53.6.1239</ArticleId><ArticleId IdType="pubmed">10522879</ArticleId></ArticleIdList></Reference><Reference><Citation>Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M. Mast Cells as Drivers of Disease and Therapeutic Targets. Trends Immunol (2018) 39:151&#x2013;62. &#xa0;10.1016/j.it.2017.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2017.10.005</ArticleId><ArticleId IdType="pubmed">29196147</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>